Are meningococci more abundant in the throats of teenagers with common wintertime viruses?

Are teenagers with wintertime viral infections such as influenza more likely to carry high numbers of meningococcal bacteria and therefore be more infectious?

Prof Adam Finn, Dr Hannah Christensen, Dr Peter Muir, Prof James Stuart, Prof Martin Maiden.
Start Date
01 Jul 2016
University of Bristol, Bristol, UK, Public Health England, Bristol, UK, University of Oxford, Oxford, UK

What is this project about?

Although meningococcal disease mostly occurs in young children the bacteria are most commonly found living in the throats of adolescents and young adults. They are transmitted between these young people, and to others, though social contact but only rarely cause disease. 

It is now known that the success of the vaccination programme against MenC was largely due to the vaccine’s ability to reduce carriage and transmission between adolescents and also from adolescents to others including younger children. For this reason, interest in understanding how meningococcal bacteria are carried and transmitted has increased. 

The research team have recently shown that adolescents are more likely to have higher numbers of meningococcal bacteria in their throats in January and February. This time of ‘high density carriage’ coincides with the peak of the influenza season. 

The aim of this project is to establish whether wintertime viral infections (such as influenza) could be associated with high carriage density of meningococcal bacteria. In other words, are people with wintertime viral infections more likely to carry high numbers of meningococcal bacteria and therefore be more infectious?

Why is this important?

With meningococcal disease, it is widely accepted that prevention is better than cure and prevention primarily means vaccines. It’s now clear for many vaccines that it is when the train of transmission is broken that really impressive disease prevention occurs and meningococcal vaccines are no exception. As a result there is an urgent need to understand better how throat carriage of meningococcus happens and find new ways of preventing it.

Potential outcomes

If viral infections like flu cause meningococcal carriage to be more common or cause people to carry higher numbers of meningococcal bacteria and so, probably, to be more infectious than others, then widespread use of flu vaccines may result in reductions in the circulation of meningococcus and so less disease. The way we use meningococcal vaccines might also be changed to focus efforts more efficiently on blocking transmission at critical times and places.

Decisions about whether or not to use vaccines depend increasingly on mathematical models. Essentially these are large sums that work out how much disease and how many deaths will be prevented and how much all of that is worth compared to the cost of buying and administering the vaccine. Often it is hard to get these sums right because it is not known exactly how well the vaccines will work. This is especially true about their ability to reduce disease by reducing circulation of the bacteria that cause disease in the population. The results of this study will help improve the information used in these kind of sums and so increase the confidence with which policy decisions about new vaccines can be made.

Since the charity was founded in 1989, we have awarded 161 research grants. The total value of our investment in vital scientific research is over £19.1 million (€24.7 million).
We take action that benefits people directly, including training health professionals and providing support and information services.
We call for positive change as a united voice against meningitis and septicaemia, and a dedicated champion for those it affects.
We've invested nearly £20 million into meningitis research since 1989. Now, we're looking back at our most incredible achievements so far.
Give researchers the clues to help defeat meningitis
Give researchers the clues to help defeat meningitis
£160/€190/$214 decodes the genetic information in a sample of meningococcal bacteria. This information helps us to track new forms of meningitis and campaign to introduce new vaccines.
Share this
Liz Rodgers
Research Projects Manager

Hi, I’m Liz and I’m MRF's Research Projects Manager.

If you’d like to know more about this area of MRF's work, do get in touch.

Tel: 0333 405 6258